Abstract
HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.
| Original language | English |
|---|---|
| Title of host publication | Clinical Dilemmas in Viral Liver Disease |
| Publisher | Wiley-Blackwell |
| Pages | 50-54 |
| Number of pages | 5 |
| ISBN (Print) | 9781405179058 |
| DOIs | |
| State | Published - Mar 10 2010 |
Fingerprint
Keywords
- Dialysis
- Hepatitis C
- Interferon
- Survival
ASJC Scopus subject areas
- Medicine(all)
Cite this
Management of HCV in Dialysis Patients. / Fabrizi, Fabrizio; Martin, Paul.
Clinical Dilemmas in Viral Liver Disease. Wiley-Blackwell, 2010. p. 50-54.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Management of HCV in Dialysis Patients
AU - Fabrizi, Fabrizio
AU - Martin, Paul
PY - 2010/3/10
Y1 - 2010/3/10
N2 - HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.
AB - HCV infection remains frequent among patients on maintenance haemodialysis, and HCV has a detrimental role on survival in this population. Recent data have been accumulated on the antiviral treatment of HCV in dialysis patients. Although response rates to conventional interferon are better in the dialysis population, tolerance to interferon monotherapy appears lower in patients on maintenance haemodialysis than in the population with intact kidney function. The most frequent side effects requiring interruption of treatment were flu-like symptoms and gastrointestinal and haematological changes. One-third of dialysis patients with chronic HCV were successfully treated with conventional or pegylated interferon monotherapy, the summary estimate for sustained virological response rate being 39% (95% CI 32, 46) and 31% (95% CI 7, 55), respectively, according to a recent meta-analysis. Preliminary evidence does not support additional benefit of monotherapy with peginterferon on the viral response in the dialysis population. Scarce data exist on combined antiviral therapy for HCV (interferon plus ribavirin) in the dialysis population, even if encouraging results in terms of viral response have been noted. The optimal antiviral treatment of chronic hepatitis C in the dialysis population is currently under investigation.
KW - Dialysis
KW - Hepatitis C
KW - Interferon
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=84886072571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886072571&partnerID=8YFLogxK
U2 - 10.1002/9781444319590.ch11
DO - 10.1002/9781444319590.ch11
M3 - Chapter
SN - 9781405179058
SP - 50
EP - 54
BT - Clinical Dilemmas in Viral Liver Disease
PB - Wiley-Blackwell
ER -